These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 9882028

  • 1. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
    Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD.
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
    [Abstract] [Full Text] [Related]

  • 2. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD.
    Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
    [Abstract] [Full Text] [Related]

  • 3. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W, Schreiber S, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U.
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000544. PubMed ID: 23076890
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV, Kane SV, Bjorkman D.
    Aliment Pharmacol Ther; 2004 Jan 15; 19(2):179-89. PubMed ID: 14723609
    [Abstract] [Full Text] [Related]

  • 9. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB, Goa KL.
    Drugs; 2002 Jan 15; 62(11):1689-705. PubMed ID: 12109930
    [Abstract] [Full Text] [Related]

  • 10. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
    Rahimi R, Nikfar S, Rezaie A, Abdollahi M.
    Dig Dis Sci; 2009 Apr 15; 54(4):712-21. PubMed ID: 18683049
    [Abstract] [Full Text] [Related]

  • 11. Balsalazide.
    Prakash A, Spencer CM.
    Drugs; 1998 Jul 15; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [Abstract] [Full Text] [Related]

  • 12. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
    Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A.
    Med Sci Monit; 2004 Nov 15; 10(11):PI126-31. PubMed ID: 15507864
    [Abstract] [Full Text] [Related]

  • 13. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD.
    Aliment Pharmacol Ther; 2002 Jan 15; 16(1):69-77. PubMed ID: 11856080
    [Abstract] [Full Text] [Related]

  • 14. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K, Williams JG.
    Aliment Pharmacol Ther; 2001 Oct 15; 15(10):1549-54. PubMed ID: 11563993
    [Abstract] [Full Text] [Related]

  • 15. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC.
    Aliment Pharmacol Ther; 2002 Jan 15; 16(1):61-8. PubMed ID: 11856079
    [Abstract] [Full Text] [Related]

  • 16. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW.
    Scand J Gastroenterol Suppl; 2002 Jan 15; (236):42-7. PubMed ID: 12408503
    [Abstract] [Full Text] [Related]

  • 17. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
    Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, Swarbrick ET, Thornton P.
    Aliment Pharmacol Ther; 1992 Oct 15; 6(5):647-52. PubMed ID: 1420754
    [Abstract] [Full Text] [Related]

  • 18. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
    Nikfar S, Rahimi R, Rezaie A, Abdollahi M.
    Dig Dis Sci; 2009 Jun 15; 54(6):1157-70. PubMed ID: 18770034
    [Abstract] [Full Text] [Related]

  • 19. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
    Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, Baron JH, Barrison IG, Polson RJ, Hoare AM.
    Aliment Pharmacol Ther; 1992 Aug 15; 6(4):479-85. PubMed ID: 1358234
    [Abstract] [Full Text] [Related]

  • 20. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000543. PubMed ID: 23076889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.